Targeting TRPA1 antagonists for nociplastic pain: systematic review and meta-analysis of preclinical evidence
Abstract
Nociplastic pain results from altered nociceptive processing without apparent tissue damage. Effective treatment remains challenging due to limited biomarker availability and poor response to conventional analgesics. Transient receptor potential ankyrin 1 (TRPA1) is a promising molecular target because of its role in pain hypersensitivity and neuroinflammatory signaling. Preclinical studies indicate that TRPA1 antagonists reduce nociception in various nociplastic pain models. However, their therapeutic significance has not been systematically evaluated. This systematic review and meta-analysis summarize preclinical evidence regarding TRPA1 antagonists as modulators of nociplastic pain hypersensitivity. The protocol was registered in PROSPERO (CRD42025629227). A systematic search of PubMed, Scopus, and Web of Science identified studies published from 2011 to 2024. Twelve in vivo rodent studies met the inclusion criteria, assessing TRPA1 antagonists in migraine-like nociception, chronic post-ischemia pain (CPIP), and reserpine-induced fibromyalgia models. Mechanical allodynia was the primary outcome. Data were pooled using a random-effects model, and heterogeneity was quantified using the I2. Study quality ranged from low to moderate, with recent publications revealing improved reporting standards and reduced risk of bias. Meta-analysis showed that TRPA1 antagonists produced consistent antinociceptive effects across nociplastic pain models, reducing mechanical and cold…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.